pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
Astellas Pharma projects
5 ClinicalTrials.gov programs sponsored by Astellas Pharma.
Astellas Pharma has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2138-CL-0101
Astellas Pharma GmbH
Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
1 trial -
2215-CL-5201
Astellas Pharma GmbH
Locally advanced or metastatic NSCLC
1 trial -
2693-CL-2101
Astellas Pharma GmbH
Hot Flush
1 trial -
A study of ASP3082 in adults with advanced solid tumors
Astellas Pharma GmbH
Solid Tumor
1 trial -
A study to find a suitable dose of ASP5834 in adults with solid tumors
Astellas Pharma GmbH
Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
1 trial
Frequently asked questions
How many clinical projects does Astellas Pharma have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.